Multitargeted receptor tyrosine kinase inhibition: An antiangiogenic strategy in non-small cell lung cancer

Cancer Treatment Reviews

Volumn 37, Issue 8, 2011, Pages 611-617

  Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Angiogenesis; FGFR; NSCLC; PDGFR; TKIs; VEGFR

Indexed keywords

AXITINIB; BEVACIZUMAB; BRIVANIB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GEMCITABINE; INTEDANIB; LINIFANIB; MOTESANIB; PACLITAXEL; PAZOPANIB; PEMETREXED; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ASCITES; ASTHENIA; BRONCHOPLEURAL FISTULA; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CONFUSION; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG MEGADOSE; DYSPNEA; ENZYME INHIBITION; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPONATREMIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PLEURA EFFUSION; PNEUMONIA; PROTEINURIA; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 80054063355     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.04.003     Document Type: Review

References (85)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Non-Small Cell Lung Cancer. V.2.2010. Available from: [accessed 8.4.2010]. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
3. Ramalingam S., Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008, 13(Suppl. 1):5-13.
4. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
5. de Marinis F., Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 2008, 13(Suppl. 1):14-20.
6. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801):249-257.
7. Folkman J., Klagsbrun M. Angiogenic factors. Science 1987, 235(4787):442-447.
8. Folkman J., Shing Y. Angiogenesis. J Biol Chem 1992, 267(16):10931-10934.
9. Klagsbrun M., Moses M.A. Molecular angiogenesis. Chem Biol 1999, 6(8):R217-R224.
10. Ellis L.M., Fidler I.J. Angiogenesis and metastasis. Eur J Cancer 1996, 32A(14):2451-2460.
11. Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001, 28(6):536-542.
12. Shibuya M., Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006, 312(5):549-560.
13. Avastin® (bevacizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; 2009.
14. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22(11):2184-2191.
15. Reck M., von P.J., Zatloukal P., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21(9):1804-1809.
16. Erber R., Thurnher A., Katsen A.D., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004, 18(2):338-340.
17. Lu C., Kamat A.A., Lin Y.G., et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 2007, 13(14):4209-4217.
18. Batchelor T.T., Sorensen A.G., di T.E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11(1):83-95.
19. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8(4):299-309.
20. Alvarez R.H., Kantarjian H.M., Cortes J.E. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006, 81(9):1241-1257.
21. Bergsten E., Uutela M., Li X., et al. PDGF-D is a specific, protease-activated ligand for the PDGF β-receptor. Nat Cell Biol 2001, 3(5):512-516.
22. Oikawa T., Onozawa C., Sakaguchi M., Morita I., Murota S. Three isoforms of platelet-derived growth factors all have the capability to induce angiogenesis in vivo. Biol Pharm Bull 1994, 17(12):1686-1688.
23. Risau W., Drexler H., Mironov V., et al. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 1992, 7(4):261-266.
24. Robinson S.P., Ludwig C., Paulsson J., Ostman A. The effects of tumor-derived platelet-derived growth factor on vascular morphology and function in vivo revealed by susceptibility MRI. Int J Cancer 2008, 122(7):1548-1556.
25. Enge M., Bjarnegard M., Gerhardt H., et al. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J 2002, 21(16):4307-4316.
26. Hellstrom M., Gerhardt H., Kalen M., et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001, 153(3):543-553.
27. Hellstrom M., Kalen M., Lindahl P., Abramsson A., Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999, 126(14):3047-3055.
28. Lindahl P., Johansson B.R., Leveen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277(5323):242-245.
29. Abramsson A., Lindblom P., Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003, 112(8):1142-1151.
30. Jain R.K., Booth M.F. What brings pericytes to tumor vessels?. J Clin Invest 2003, 112(8):1134-1136.
31. Dong J., Grunstein J., Tejada M., et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004, 23(14):2800-2810.
32. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111(9):1287-1295.
33. Mancuso M.R., Davis R., Norberg S.M., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006, 116(10):2610-2621.
34. Benjamin L.E., Hemo I., Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998, 125(9):1591-1598.
35. Reinmuth N., Liu W., Jung Y.D., et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 2001, 15(7):1239-1241.
36. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103(2):159-165.
37. Wilkinson-Berka J.L., Babic S., De G.T., et al. Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am J Pathol 2004, 164(4):1263-1273.
38. Korc M., Friesel R.E. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009, 9(5):639-651.
39. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005, 16(2):159-178.
40. Murakami M., Simons M. Fibroblast growth factor regulation of neovascularization. Curr Opin Hematol 2008, 15(3):215-220.
41. Nissen L.J., Cao R., Hedlund E.M., et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007, 117(10):2766-2777.
42. Wedge S.R., Kendrew J., Hennequin L.F., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005, 65(10):4389-4400.
43. Relf M., LeJeune S., Scott P.A., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997, 57(5):963-969.
44. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8(8):592-603.
45. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8(8):579-591.
46. Marty M., Pivot X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer 2008, 44(7):912-920.
47. Sebolt-Leopold J.S., English J.M. Mechanisms of drug inhibition of signalling molecules. Nature 2006, 441(7092):457-462.
48. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19):7099-7109.
49. Murphy D.A., Makonnen S., Lassoued W., Feldman M.D., Carter C., Lee W.M. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 2006, 169(5):1875-1885.
50. Blumenschein G.R., Gatzemeier U., Fossella F., et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009, 27(26):4274-4280.
51. Schiller J.H., Lee J.W., Hanna N.H., Traynor A.M., Carbone D.P. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol 2008, 26. (15S).
52. Schiller J.H., Flaherty K.T., Redlinger M., et al. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: a phase I subset analysis. J Clin Oncol 2006, 24(18S). Abstract 7194.
53. Scagliotti G., Novello S., von P.J., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(11):1835-1842.
54. Bayer Healthcare Pharmaceuticals Inc., Onyx Pharmaceuticals Inc. Phase 3 trial of Nexavar in first-line advanced non-small cell lung cancer does not meet primary endpoint of overall survival. Press release. June 14, 2010. Available from: [accessed 27.7.2010]. http://www.onyx-pharm.com/view.cfm/685/Phase-3-Trial-of-Nexavar-in-First-Line-Advanced-Non-Small-Cell-Lung-Cancer-Does-Not-Meet-Primary-Endpoint-of-Overall-Survival.
55. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003, 2(5):471-478.
56. SUTENT® (sunitinib malate) capsules, oral [package insert]. New York, NY: Pfizer Inc.; 2010.
57. Socinski M.A., Novello S., Brahmer J.R., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008, 26(4):650-656.
58. Novello S., Scagliotti G.V., Rosell R., et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009, 101(9):1543-1548.
59. Groen H.J.M., Socinski M.A., Grossi F., et al. Randomized phase II study of sunitinib plus erlotinib versus placebo plus erlotinib for the treatment of metastatic Non-small Cell Lung Cancer. Ann Oncol 2010, 21(Suppl. 8):viii139.
60. Laurie S.A., Gauthier I., Arnold A., et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008, 26(11):1871-1878.
61. Goss G.D., Arnold A., Shepherd F.A., et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J Clin Oncol 2010, 28(1):49-55.
62. Gadgeel S.M., Wozniak A., Edelman M.J., et al. Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). J Clin Oncol 2009, 27(15S). Abstract e19007.
63. Hu-Lowe D.D., Zou H.Y., Grazzini M.L., et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008, 14(22):7272-7283.
64. Schiller J.H., Larson T., Ou S.I., et al. Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial. J Clin Oncol 2007, 25(18S). Abstract 7507.
65. Martin L.P., Kozloff M.F., Krzakowski M., et al. Axtinib (AG-013736; AG) combined with chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol 2009, 27(15S). Abstract 3559.
66. Albert D.H., Tapang P., Magoc T.J., et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006, 5(4):995-1006.
67. Tan E, Salgia R, Besse B, et al. ABT-869 in non-small cell lung cancer (NSCLC): interim results. J Clin Oncol 2009;27(15S). Abstract 8074.
68. Polverino A., Coxon A., Starnes C., et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006, 66(17):8715-8721.
69. Blumenschein GR, Kabbinavar FF, Menon H, et al. Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15s):7528.
70. Bhide R.S., Cai Z.W., Zhang Y.Z., et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 2006, 49(7):2143-2146.
71. Laird A.D., Vajkoczy P., Shawver L.K., et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000, 60(15):4152-4160.
72. Laschke M.W., Elitzsch A., Vollmar B., Vajkoczy P., Menger M.D. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 2006, 21(1):262-268.
73. Hilberg F., Roth G.J., Krssak M., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008, 68(12):4774-4782.
74. Reck M., Kaiser R., Eschbach C., et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011, [Epub ahead of print].
75. van Heeckeren W.J., Ortiz J., Cooney M.M., Remick S.C. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?. J Clin Oncol 2007, 25(21):2993-2995.
76. Lacouture M.E., Wu S., Robert C., et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008, 13(9):1001-1011.
77. Ellis P.M., Kaiser R., Zhao Y., Stopfer P., Gyorffy S., Hanna N. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 2010, 16(10):2881-2889.
78. Kumar R., Knick V.B., Rudolph S.K., et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007, 6(7):2012-2021.
79. Altorki N., Heymach J., Guarino M., et al. Phase II study of pazopanib (GW786034) given preoperatively in stage II non-small cell lung cancer (NSCLC): a proof-of-concept study. Ann Oncol 2008, 19(Suppl. 8):viii89-viii124.
80. Kim D.W., Jo Y.S., Jung H.S., et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006, 91(10):4070-4076.
81. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9(1):327-337.
82. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101(9):3597-3605.
83. Gutierrez M., Kummar S., Allen D., et al. A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol 2008, 26(15S). Abstract 19084.
84. Adjei A.A., Molina J.R., Hillman S.L., et al. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 2007, 25(18S). Abstract 7547.
85. Reck M., Frickhofen N., Gatzemeier U., et al. A phase I dose escalation study of sunitinib in combination with gemcitabine+cisplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007, 25(18S). Abstract 18057.